Results 201 to 210 of about 1,822 (274)
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen. [PDF]
Coratti G +34 more
europepmc +1 more source
UEG Week 2025 Oral Presentations
United European Gastroenterology Journal, Volume 13, Issue S8, Page S7-S188, October 2025.
wiley +1 more source
Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy. [PDF]
Dobelmann V +10 more
europepmc +1 more source
UEG Week 2025 Moderated Posters
United European Gastroenterology Journal, Volume 13, Issue S8, Page S189-S802, October 2025.
wiley +1 more source
Spinal muscular atrophy in an upper-middle-income nation before the advent of reimbursed disease-modifying therapies. [PDF]
Sakpichaisakul K +6 more
europepmc +1 more source
UEG Week 2025 Poster Presentations
United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley +1 more source
Pediatric non-Hodgkin lymphoma as a rare cause of spinal cord injury: When lymphoma hides in the canal. [PDF]
Zama D +7 more
europepmc +1 more source
Telemedicine for Personalized Nutritional Intervention of Rare Diseases: A Narrative Review on Approaches, Impact, and Future Perspectives. [PDF]
Eletti F +9 more
europepmc +1 more source
Spinal muscular atrophy in childhood
Diagnosis and classification of spinal muscular atrophy (SMA) in childhood are based on clinical, electrophysiological, and histological studies. The concept of maturational arrest of motoneurons and their targets (muscle cells in SMA type I) is documented by ultrastructural and immunohistochemical data.
Anna Fidziańska
openalex +4 more sources

